GlycoTreat receives EFRO grant from Kansen voor West to support the development of Breakthrough Allergy Immunotherapy

Amersfoort, The Netherlands – 16 April 2025.

GlycoTreat, a pioneering biotechnology company developing immunotherapies for chronic allergic conditions, today announced that their IMMUNITAS project - developing a next-generation immunotherapy for canine atopic dermatitis, has been awarded funding by Kansen voor West (EFRO).

Together with GlycoTreat's partner Utrecht University Veterinary Department, GlycoTreat is advancing our innovative, glycan-based platform technology to improve the lives of dogs with allergic skin disease.

Thank you to Kansen voor West for supporting this exciting IMMUNITAS program!

Founded by Ina Margaretha Rijnhout (CEO) and Prof. Yvette van Kooyk (CSO), GlycoTreat is building a first-in-class glyco-immunology technology platform that reprograms the immune system to restore tolerance.

> *"Our mission is ambitious yet focused: pursuing a groundbreaking treatment for allergic conditions through precision immunotherapy,"* said Ina Margaretha Rijnhout, CEO of GlycoTreat. *This EFRO funding from Kansen voor West empowers us to advance our program in Canine Allergic Dermatitis toward clinical validation."*

The company's approach centers on tolerogenic glycans inducing long-lasting immune tolerance. By targeting the underlying cause of allergies, GlycoTreat's GlycoTx™ platform offers a potentially curative alternative to symptomatic treatments.

With this funding, GlycoTreat is actively expanding its collaborations with academic institutions and pharmaceutical partners, aiming to bring the next generation of allergen-specific immunotherapies to clinical application in both humans and animals.

Contact:
Ina Margaretha Rijnhout, CEO | irijnhout@glycotreat.com | www.glycotreat.com | https://www.linkedin.com/company/glycotreat/

kansen voor west

Medegefinancierd door de Europese Unie